gsk1120212
BRAF V600 Mutation
Xynomic Pharmaceuticals, Inc.Phase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the BRAF V600 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Binimetinib UNICANCER | Phase 2 | BB |
Encorafenib UNICANCER | Phase 2 | B |
Nivolumab H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
Cobimetinib ABM Therapeutics Corporation | Phase 2 | B |
Carboplatin Guangdong Provincial People's Hospital | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
gsk1120212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →